The rise in high fructose corn syrup (HFCS) consumption over the past 40 years since its introduction as a popular sweetener in the United States has led to much concern regarding its contribution to the rise in obesity (1), diabetes (2) and related cardiometabolic disorders (3).Unlike sucrose which contains equal proportions of fructose and glucose bound by an α-glycosidic bond, HFCS contains 42-55% of fructose to glucose in a free (unbound) form (4). Despite these differences in composition, both sugars possess identical energy contribution on a gram to gram basis (4). However, the higher ratio of fructose to glucose in HFCS has led to the hypothesis that HFCS may uniquely contribute to cardiometabolic risk, more so than sucrose, through proposed differences in fructose metabolism, endocrine and hedonic properties (5). We will conduct a series of systematic reviews and meta-analyses to assess the role of HFCS versus sucrose under energy matched (isocaloric) conditions on cardiometabolic risk.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Body weight and measures of adiposity analysis
Timeframe: Up to 20 years
Glycemic control analysis
Timeframe: Up to 20 years
Blood Lipids analysis
Timeframe: Up to 20 years
Blood pressure analysis
Timeframe: Up to 20 years
Uric acid analysis
Timeframe: Up to 20 years
Non-Alcoholic Fatty Liver Disease (NAFLD) and ectopic fat Analysis
Timeframe: Up to 20 years
Inflammation analysis
Timeframe: Up to 20 years